

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities in the Company.*

## **Fameglow Holdings Limited**

**亮晴控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code on Main Board: 3774)**

**(Stock Code on GEM: 8603)**

### **TRANSFER OF LISTING FROM GEM TO THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED**

**Financial Advisor to the Company**



This announcement is made by the Company pursuant to Rule 9B.08 of the Main Board Listing Rules.

On 8 December 2025, the Application was made by the Company to the Stock Exchange for the listing of and permission to deal in the Shares on the Main Board by way of the Transfer of Listing pursuant to Chapter 9B of the Main Board Listing Rules.

The Board is pleased to announce that the approval-in-principle for the Transfer of Listing was granted by the Stock Exchange on 22 June 2026.

As at the date of this announcement, save for the following pre-conditions which are expected to be fulfilled on 30 June 2026, being the date of the commencement of dealings in the Shares on the Main Board, all applicable pre-conditions for the Transfer of Listing had been fulfilled in relation to the Company and the Shares:

- (a) On the basis that the volume weighted average market capitalization (within the meaning of Chapter 9B of the Main Board Listing Rules) of the Company over the Relevant Period is approximately HK\$3,054.4 million, which is more than HK\$500,000,000 as required in Rule 8.09(2) of the Main Board Listing Rules, the Company expects that the volume weighted average market capitalization of the Company as required in Rule 9B.03(2) of Main Board Listing Rules can be fulfilled; and

- (b) On the basis that not less than 50% of all trading days over the Relevant Period on which the Company had a daily turnover of its Shares of at least HK\$50,000, the Company expects that the daily turnover of its Shares as required in Rule 9B.03(5) of Main Board Listing Rules can be fulfilled.

The last day of dealings in the Shares on GEM (stock code on GEM: 8603) will be on 29 June 2026. It is expected that dealings in the Shares on the Main Board (stock code on the Main Board: 3774) will commence at 9:00 a.m. on 30 June 2026.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.**

## **INTRODUCTION**

This announcement is made by the Company pursuant to Rule 9B.08 of the Main Board Listing Rules.

Reference is made to the announcement issued by the Company dated 8 December 2025 in relation to the submission of the formal application to the Stock Exchange for the Transfer of Listing pursuant to Chapter 9B of the Main Board Listing Rules.

## **TRANSFER OF LISTING OF THE SHARES FROM GEM TO THE MAIN BOARD**

On 8 December 2025, the Application was made by the Company to the Stock Exchange for the listing of and permission to deal in the Shares on the Main Board by way of the Transfer of Listing pursuant to Chapter 9B of the Main Board Listing Rules.

The Board is pleased to announce that the approval-in-principle for the Transfer of Listing was granted by the Stock Exchange on 22 June 2026.

As at the date of this announcement, save for the following pre-conditions which are expected to be fulfilled on 30 June 2026, being the date of the commencement of dealings in the Shares on the Main Board, all applicable pre-conditions for the Transfer of Listing had been fulfilled in relation to the Company and the Shares:

- (a) On the basis that the volume weighted average market capitalization (within the meaning of Chapter 9B of the Main Board Listing Rules) of the Company over the Relevant Period is approximately HK\$3,054.4 million, which is more than HK\$500,000,000 as required in Rule 8.09(2) of the Main Board Listing Rules, the Company expects that the volume weighted average market capitalization of the Company as required in Rule 9B.03(2) of Main Board Listing Rules can be fulfilled; and
- (b) On the basis that not less than 50% of all trading days over the Relevant Period on which the Company had a daily turnover of its Shares of at least HK\$50,000, the Company expects that the daily turnover of its Shares as required in Rule 9B.03(5) of Main Board Listing Rules can be fulfilled.

The last day of dealings in the Shares on GEM (stock code on GEM: 8603) will be on 29 June 2026. It is expected that dealings in the Shares on the Main Board (stock code on the Main Board: 3774) will commence at 9:00 a.m. on 30 June 2026.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.**

## **REASONS FOR THE TRANSFER OF LISTING**

The Board believes that the Transfer of Listing from the GEM to the Main Board will significantly elevate the corporate profile and public recognition of the Company, given the Main Board's larger total market capitalisation, higher trading liquidity, and greater international visibility. As an established medical aesthetic service provider in Hong Kong, the Group views the more stringent listing requirements and the premium status associated with the Main Board reflecting its sound operational achievements and market position. This enhanced standing is expected to strengthen the Company's ability to attract and retain quality customers, business partners, and talents, while also enabling it to seize new business opportunities more effectively.

On the other hand, the Board considers that a Main Board listing will broaden the Company's access to a more diverse range of investors, including institutional, professional, and international participants, thereby expanding and diversifying the shareholder base. The Transfer of Listing is also anticipated to improve the Company's financing flexibility, providing access to a wider array of debt financing options on more competitive terms. This will support the optimization of the capital structure and offer greater strategic financial management.

Based on the foregoing, the Board is of the view that the Transfer of Listing will contribute positively to the sustainable growth and long-term development of the Group, strengthening its market position and supporting long-term value creation for the Company and its Shareholders.

As at the date of this announcement, the Board has no immediate plans to change the nature of the business of the Group following the Transfer of Listing.

## **INFORMATION ON THE GROUP**

The Group is a medical aesthetic service provider in Hong Kong and operates medical aesthetic centres under the brand "per Face", started using the brand since 2010, providing non-surgical medical aesthetic services.

### **Principal Business**

The Group is a medical aesthetic service provider, has been principally engaged in provision of non-surgical medical aesthetic services, traditional beauty services and sale of associated skincare products, in Hong Kong. The Group operates centres in prime locations of Causeway Bay, Tsim Sha Tsui, Mong Kok and Central, etc. in Hong Kong and in Macau. The Group strives to provide treatment solutions to the clients to help the clients maintain and enhance their skin conditions and physical appearance.

The non-surgical medical aesthetic services can generally be categorised as (i) energy-based procedures; and (ii) minimally invasive procedures. The Group is equipped with various treatment devices with prevailing technologies, which enable the Group's doctors and trained therapists to provide various treatment procedures to cater for the individual needs of each client. Energy-based procedures are non-invasive aesthetic treatments that utilise specific forms of physical energy — such as radiofrequency, ultrasound, laser, or pulsed light — to treat skincare and body contouring concerns. Minimally invasive procedures are procedures which produce relatively minor damage of body tissue and do not involve entering the body through surgical incisions into the skin with an operative procedure and closure with sutures. Examples include injections of botulinum toxin A (i.e. Botox) and dermal fillers. These procedures are categorised based on the nature and type of treatments for financial reporting purpose rather than based on applicable laws and regulations.

According to the Advisory Note on the Provision of Cosmetic Procedures (for beauty service providers) issued by the Department of Health of Hong Kong in November 2013, procedures that involve injection of substances into the body (including botulinum toxin A and dermal fillers) should only be performed by registered medical practitioner (i.e. doctor in such cases). All minimally invasive procedures are performed by our Group's doctors only, and the place to carry out such treatments is subject to the licencing requirements of Private Healthcare Facilities Ordinance (Cap. 633, the “**PHFO**”). The Group has submitted applications for clinic licences for the centres that are applicable to the requirements under the PHFO. The relevant licence applications are still under review, and no decisions have yet been issued as at the Latest Practicable Date. For further details, please refer to the section headed “Compliance” in this announcement below.

To complement the Group's non-surgical medical aesthetic services, the Group also offers a range of traditional beauty services and branded skincare products sourced from the Group's distributors to its clients to improve their physical appearance, skin condition as well as to enhance the results of non-surgical medical aesthetic treatments. The Group's traditional beauty services include facials as well as nail and massage services. As at the Latest Practicable Date, the Group offered nine skincare brands with products including cleanser, toner, serum, moisturiser, eye care product and mask, etc.

In order to seize the opportunity created by increasing customer demands especially after the COVID-19 pandemic, the Group significantly expanded its operation scale by opening several new centres during the Track Record Period. During the year ended 31 March 2025, the Group has launched a new flagship centre in Causeway Bay, two new centres in Tsim Sha Tsui, a new centre in Sha Tin, and a new centre in Kowloon Bay and a new centre in Macau. During the year ended 31 March 2026, the Group further launched five new centres in Mong Kok, Kowloon Tong, Lai Chi Kok, Central and Wanchai respectively to further expand the Group's customer reach. The number of centres has grown from 6 at the beginning of the Track Record Period to 16 at the end of the Track Record Period. As at the Latest Practicable Date, the Group operates 15 centres in Hong Kong and 1 centre in Macau.

Due to the ongoing expansion in terms of the number of centres, the Group continuously attracted new customers. The Group had approximately 13,000, 19,000 and 24,000 active customers (*note*) during each of the year ended 31 March 2024, 2025 and 2026. The average

*Note:* Active customers refer to customers who have performed at least one treatment session during the respective financial years.

treatment spending per customer calculated on revenue-recognition basis was approximately HK\$22,000, HK\$23,000 and HK\$24,000 for each of the year ended 31 March 2024, 2025 and 2026, and the average treatment spending per customer calculated on actual spending basis was approximately HK\$19,000, HK\$22,000 and HK\$25,000 for each of the year ended 31 March 2024, 2025 and 2026. The average treatment spending per customer was higher for the year ended 31 March 2026 as compared with the previous year mainly because the Company put in more effort to promote treatments covering multiple parts of the face and/or the body, leading to higher treatment spending. The average treatment spending per customer calculated on revenue-recognition basis was higher than the one calculated on actual spending basis for the year ended 31 March 2024 mainly because the containment measures of the COVID-19 pandemic were lifted in Hong Kong during the year ended 31 March 2023. Subsequently, the Group has actively encouraged package customers to utilise their unused package treatments, thus boosting the average treatment spending per customer calculated on revenue-recognition basis for the year ended 31 March 2024. Besides, the Group emphasised the selling of prepaid packages with less treatment sessions during the year ended 31 March 2024. These prepaid packages with less treatment sessions are generally utilised within one year, leading to higher average treatment spending per customer calculated on revenue-recognition basis in the next year (i.e. year ended 31 March 2025). For the years ended 31 March 2024, 2025 and 2026, prepaid packages with 6 or fewer treatment sessions accounted for approximately 70%, 64% and 65% of total sales amounts, respectively.

The Group believes that the expansion will enable us to deepen the market penetration in Hong Kong and improve the Group's profitability. The Group will also take advantage of its enlarging geographical presence to attract new and more diverse customers. Along with the strategic expansion of its medical aesthetic centre network, the Group will sharpen its competitive advantage by extending the spectrum of the treatment services offered.

The following table sets forth the movement of number of centres for the Track Record Period:

	<b>For the year ended 31 March</b>		
	<b>2024</b>	<b>2025</b>	<b>2026</b>
As of the beginning of year	6	6	11
Additions ( <i>note</i> )	—	6	5
Closure	—	(1)	—
As of the end of the year	<u>6</u>	<u>11</u>	<u>16</u>

*Note:* For the purpose of the above table, a centre is considered opened when the lease for the centre has started.

The Group started using the brand “per Face” in 2010, and brought into operation the brands “20 Beauty” and “20 Laser” in 2020 to target young ladies and gentlemen looking for hair removal and facial services.

To penetrate the market and diversify the Group’s customer base, the Group has brought into operation several new brands during the Track Record Period. The new brands brought into operation during the year ended 31 March 2024 include “**Angus’ Beauty Concept**” which offers high-ended services to the Group’s valuable customers, “**LASERKOOL**” which specializes in hair removal treatment for men, “**Face It**” which provides trendy and quality services to teenagers. “**Dr. Healthlase**” which offers medically-based laser skincare services and “**The Organic Pharmacy**” which provides medical aesthetic treatments using skincare products of the same brand. During the year ended 31 March 2025, the Group further brought into operation the brands “**MediHair**”, “**perFACE Essential**” and “**iFACES**” to target customers looking for hair care services, life beauty services and customers in Macau respectively.

The following table sets forth the details of the Group’s brands during the Track Record Period:

Brand	Commencement date	Target customers	Types of services provided	Number and location of centres <i>(note)</i>		
				Year ended 31 March		
				2024	2025	2026
<b>Existing brand</b>						
perFACE	Sep-2010	Mature women	Medical aesthetic services	6 (HK:3; Kln:3)	10 (HK:4; Kln:6)	12 (HK:3; Kln:7; NT:1; Macau:1)
20 Beauty	Jan-2020	Young women	Medical aesthetic services	6 (HK:3; Kln:3)	9 (HK:4; Kln:5)	9 (HK:4; Kln:5)
20 Laser	Jan-2020	Men looking for hair removal and facial services	Hair removal and facial services	5 (HK:2; Kln:3)	10 (HK:4; Kln:6)	10 (HK:3; Kln:7)
<b>New brand</b>						
The Organic Pharmacy	Apr-2023	Customers looking for medical aesthetic services	Medical aesthetic services	3 (HK:3)	2 (HK:1; Kln:1)	0
Face IT	Nov-2023	Teenagers looking for medical aesthetic services	Medical aesthetic services	2 (Kln:2)	7 (HK:3; Kln:4)	2 (Kln:2)
LaserKool	Jan-2024	Customers looking for hair removal services	Hair removal services	1 (Kln:1)	6 (HK:3; Kln:3)	6 (HK:2; Kln:4)
Dr. Healthlase	Jan-2024	Customers looking for laser and medical skin services	Laser and medical skin services	3 (HK:1; Kln:2)	7 (HK:3; Kln:4)	3 (HK:2; Kln:1)
Angus’ Beauty Concept	Jan-2024	Customers looking for medical aesthetic services	Medical aesthetic services	1 (HK:1)	1 (HK:1)	1 (HK:1)
MediHair	Aug-2024	Customers looking for hair care services	Hair care services	0	1 (HK:1)	1 (HK:1)
iFACES	May-2024	Customers in Macau	Medical aesthetic services	0	1 (Macau:1)	1 (Macau:1)
perFACE Essential	Jul-2025	Customers looking for life beauty services	Life beauty services	0	0	3 (HK:2; Kln:1)

*Note:* In the above table, HK denotes Hong Kong Island in Hong Kong; Kln denotes Kowloon in Hong Kong; NT denotes the New Territories in Hong Kong.

The aggregate number of centres in the above table is larger than the number of centres that the Group operates because the Group operates more than one brand in most of the individual centres.

During the Track Record Period, prices of the Group's prepaid treatment packages ranged from HK\$600 to approximately HK\$302,000, depending on the type of treatment service and number of treatment sessions. The average value of the prepaid packages for the three years ended 31 March 2024, 2025 and 2026 were approximately HK\$9,700, HK\$9,500 and HK\$10,400 respectively. The Group's standard prepaid packages generally have a validity period of up to 24 months from the date of purchase. Upon expiry of the validity period, the remaining deferred revenue in respect of the prepaid packages not utilised will be recognised as revenue from expiry of prepaid treatments. If the relevant client is considered to be a client with good spending history, the Group's sales consultant may voluntarily extend the validity of the prepaid package for such client if such client requests for an extension upon being notified that his/her prepaid package will soon be expired. Apart from clients who have good spending history with the Group, the Group may also, with the final approval of the general manager of operation and/or operation manager on a case-by-case basis and in their absolute discretion, allow other clients to extend the validity period of the prepaid packages for an appropriate period. Examples of valid reasons for extension include changes of the client's skin/health condition, departure from Hong Kong and pregnancy. etc.

The following table sets forth the respective number, price range and revenue of one-off and prepaid treatments performed under each type of services during the Track Record Period:

	2024			Year ended 31 March 2025			2026					
	Number of service	Revenue (Note) (HK\$'000)	Average revenue (HK\$/service)	Price range (HK\$/service)	Number of service	Revenue (Note) (HK\$'000)	Average revenue (HK\$/service)	Price range (HK\$/service)	Number of service	Revenue (Note) (HK\$'000)	Average revenue (HK\$/service)	Price range (HK\$/service)
<i>Prepaid packages</i>												
— Energy-based procedures	162,944	256,971	1,577	500–54,000	221,544	382,531	1,727	500–58,000	230,242	512,274	2,225	500–44,800
— Minimally invasive procedures	557	2,721	4,885	300–32,200	1,355	5,746	4,241	300–32,200	854	3,810	4,461	300–32,000
— Traditional beauty services	19,413	9,939	512	300–5,600	22,501	12,235	544	300–5,600	43,516	27,327	628	300–5,000
	182,914	269,631	1,474		245,400	400,512	1,632		274,612	543,411	1,979	
<i>One-off treatment</i>												
— Minimally invasive procedures	4,433	16,500	3,722	2,000–11,800	7,731	27,399	3,544	1,500–14,000	6,564	26,026	3,965	1,500–19,800
	187,347	286,131	1,527		253,131	427,911	1,690		281,176	569,437	2,025	

*Note:* the amounts represent revenue recognised from provision of treatment services and expiry of prepaid treatment packages.

The average revenue has grown gradually from approximately HK\$1,527 per service for the year ended 31 March 2024 to approximately HK\$2,025 per service for the year ended 31 March 2026, driven mainly by the changes in the average revenue for energy-based procedures, which accounted for more than 85% of the Group's revenue for treatment services and packages throughout the Track Record Period. The average revenue for energy-based procedures has increased from approximately HK\$1,577 per service for the year ended 31 March 2024 to approximately HK\$1,727 per service for the year ended 31 March 2025. Such increase was mainly due to the growing proportion of radiofrequency treatment (with higher average revenue of approximately HK\$9,216 per service for the year ended 31 March 2025) among energy-based procedures during the above-mentioned years, with the revenue from radiofrequency treatments as a percentage of all energy-based procedures increasing from approximately 22.0% for the year ended 31 March 2024 to approximately 34.6% for the year ended 31 March 2025 due to the increase in popularity of this service. The average revenue for energy-based procedures continued to grow to approximately HK\$2,225 per service for the year ended 31 March 2026 driven by the increase in average revenue for radiofrequency treatment to approximately HK\$10,652 per service for the year ended 31 March 2026. During the year ended 31 March 2026, due to the Group's promotion effort to market integrated multi-area treatments in one session, such as combined treatments for face, neck and chest, more bundled service options were chosen and the average revenue for single treatment sessions increased.

The Group is seeking to extend its service offerings from external aesthetic treatments to a comprehensive beauty and wellness solution. In line with this development strategy, on 27 October 2025, the Group entered into a joint venture agreement with a pharmaceutical company from Japan and a Singapore headquartered commercial biotechnology company to establish a joint venture in Hong Kong. The joint venture will be principally engaged in the research and development and sales of anti-ageing products and solutions in Hong Kong and the selected Asia Pacific countries. The joint venture has yet to commence business. The Group is in the course of identifying and communicating with potential vendors and customers and negotiation with other shareholders of the joint ventures in relation to the development of technologies, services and products.

On 3 October 2024, the Company entered into a non-legally binding memorandum of understanding (the "MOU") with Mr. Luk Ngai Keung ("Mr. Luk"). Pursuant to the MOU, the Company and Mr. Luk have agreed to develop an all-dimensional cooperation and to explore various opportunities to continue the business operation of certain beauty centres previously operated by Mr. Luk. Subsequently, on 20 November 2024, the Company executed an equipments/instrument transfer agreement with Mr. Luk and his wholly-owned company. Pursuant to the transfer agreement, the Company acquired a portfolio of aesthetic devices and equipment from them. This transaction has been completed.

## Summary of the Company's Financial Information

The following table sets forth some key financial information of the Company as extracted from the consolidated financial statements of the Company for the three years ended 31 March 2024, 2025 and 2026:

	<b>For the year ended 31 March</b>		
	<b>2024</b>	<b>2025</b>	<b>2026</b>
	<i>(audited)</i> <i>HK\$'000</i>	<i>(audited)</i> <i>HK\$'000</i>	<i>(audited)</i> <i>HK\$'000</i>
Revenue	299,364	435,274	589,794
Cost of inventories and consumables	(38,473)	(46,468)	(62,016)
Other income and gains or losses, net	2,160	5,095	1,302
Gain on disposal of a subsidiary	858	—	—
Staff costs	(100,292)	(170,354)	(240,865)
Rental and related expenses	(7,012)	(11,039)	(13,569)
Depreciation of property, plant and equipment	(25,775)	(28,503)	(39,511)
Depreciation of right-of-use assets	(20,450)	(31,199)	(40,951)
Other expenses	(62,944)	(93,716)	(127,606)
Finance costs	(3,155)	(4,087)	(4,571)
	<hr/>	<hr/>	<hr/>
Profit before taxation	44,281	55,003	62,007
Income tax expense	(3,530)	(9,275)	(7,366)
	<hr/>	<hr/>	<hr/>
Profit attributable to owners of the Company	<u>40,751</u>	<u>45,728</u>	<u>54,641</u>

	<b>As at 31 March</b>		
	<b>2024</b>	<b>2025</b>	<b>2026</b>
	<i>(audited)</i>	<i>(audited)</i>	<i>(audited)</i>
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
<b>Non-current assets</b>			
Property, plant and equipment	63,435	99,107	119,934
Right-of-use assets	33,126	75,759	86,812
Deposits and prepayments	12,726	14,977	34,046
Contract costs	898	530	621
Deferred tax assets	<u>1,572</u>	<u>2,329</u>	<u>5,391</u>
	111,757	192,702	246,804
<b>Current assets</b>			
Inventories	9,435	10,835	20,938
Trade receivables, deposits and prepayments	30,522	80,921	71,486
Contract costs	6,171	4,738	6,984
Promissory note receivable	17,287	—	—
Bank balances and cash	<u>19,309</u>	<u>40,615</u>	<u>110,693</u>
	82,724	137,109	210,101
<b>Current liabilities</b>			
Trade and other payables and accruals	(23,895)	(69,213)	(36,526)
Contract liabilities	(58,982)	(54,938)	(81,802)
Tax payables	(2,646)	(2,356)	(4,472)
Bank borrowings	(10,019)	(12,962)	(31,619)
Lease liabilities	(15,988)	(36,192)	(43,123)
Provisions	<u>—</u>	<u>(1,262)</u>	<u>(600)</u>
	(111,530)	(176,923)	(198,142)
<b>Net current assets/(liabilities)</b>	(28,806)	(39,814)	11,959
Non-current liabilities	<u>(22,699)</u>	<u>(46,799)</u>	<u>(51,700)</u>
<b>Net assets</b>	<u><u>60,252</u></u>	<u><u>106,089</u></u>	<u><u>207,063</u></u>

## Management Discussion and Analysis

### Revenue

The revenue of the Group amounted to approximately HK\$435.3 million for the year ended 31 March 2025 and approximately HK\$299.4 million for the year ended 31 March 2024 which represented an increase of approximately HK\$135.9 million or 45.4% as compared with the corresponding financial year of 2024. The increase was primarily attributable to the success of the new brands brought into operation and the new prime centres launched in Tsim Sha Tsui, Sha Tin and Kowloon Bay, and the flagship centre launched in Causeway Bay during the year ended 31 March 2025.

The Group's revenue grew by approximately HK\$154.5 million or 35.5% from approximately HK\$435.3 million for the year ended 31 March 2025 to approximately HK\$589.8 million for the year ended 31 March 2026. Such growth was mainly driven by revenue contribution from centres newly opened during the Track Record Period. The revenue recognised from provision of treatment services from new centres that opened during the Track Record Period was approximately HK\$344.3 million for the year ended 31 March 2026, accounting for approximately 60.5% of the overall revenue recognised from provision of treatment services.

The following table sets forth the breakdown of revenue recognised from provision of treatment services derived from existing, new and closed centres during the Track Record Period:

	For the year ended 31 March		
	2024	2025	2026
	HK\$'000	HK\$'000	HK\$'000
<b>Revenue recognised from provision of treatment services</b>			
Revenue from centres closed during the Track Record Period	94,733	21,251	—
Revenue from centres that operated throughout the Track Record Period	189,861	252,288	224,716
Revenue from new centres that opened during the Track Record Period	—	153,449	344,283
	<u>284,594</u>	<u>426,988</u>	<u>568,999</u>

In order to seize the opportunity created by increasing customer demands, the Group significantly expanded its operation scale by opening several new centres during the Track Record Period. The number of centres has grown from 6 at the beginning of the Track Record Period to 16 at the end of the Track Record Period. The opening of new centres contributed substantially to the continuous growth in revenue during the Track Record Period. The revenue recognised from provision of treatment services increased by approximately HK\$284.4 million since the year ended 31 March 2024 to the year ended 31 March 2026. Out of such growth, the revenue from centres that operated throughout the Track Record Period has increased moderately by approximately HK\$34.9 million since the year ended 31 March 2024 to the year ended 31 March 2026. The revenue from centres that opened during the Track Record Period has increased significantly by approximately HK\$344.3 million since the year ended 31 March 2024 to the year ended 31 March 2026. New centres that opened during the Track Record Period contributed approximately 0%, 35.9% and 60.5% of revenue from provision of treatment services for each of the year ended 31 March 2024, 2025 and 2026.

The following table sets forth the breakdown of revenue from provision of treatment services from existing brands and new brands brought into operation during the Track Record Period:

	<b>For the year ended 31 March</b>		
	<b>2024</b>	<b>2025</b>	<b>2026</b>
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
<b>Revenue recognised from provision of treatment services</b>			
Revenue from brands that operated throughout the Track Record Period	279,322	372,369	513,374
Revenue from new brands brought into operation during the Track Record Period	<u>5,272</u>	<u>54,619</u>	<u>55,625</u>
	<u>284,594</u>	<u>426,988</u>	<u>568,999</u>

At the beginning of the Track Record Period, the Group had three existing brands, namely “per Face”, “20 Beauty” and “20 Laser”. To penetrate the market and diversify the Group’s customer base, the Group has brought into operation 8 new brands during the Track Record Period. These new brands have contributed approximately HK\$5.3 million, HK\$54.6 million and HK\$55.6 million revenue from the provision of treatment services for each of the year ended 31 March 2024, 2025 and 2026 respectively, representing 1.9%, 12.8% and 9.8% of the revenue from the provision of treatment services for each of the year ended 31 March 2024, 2025 and 2026 respectively. The three existing brands at the beginning of the Track Record Period remain the Group’s major and substantial revenue contributor, with the revenue from the provision of treatment services growing considerably from approximately HK\$279.3 million for the year ended 31 March 2024 to HK\$513.4 million for the year ended 31 March 2026. This was attributed to the increase in number of new centre operated under these existing brands during the Track Record Period.

### ***Other income and gains or losses, net***

Other income and gains for the year ended 31 March 2025 mainly represent accruals written back of approximately HK\$2.2 million. The write-back results from a resolved legal dispute with the landlord of one of the Group's closed medical centres. The Group accrued approximately HK\$4.0 million for unpaid rent from 2022, which the Group withheld due to the failure of the landlord to fix serious water leakage in the property. It was settled during the year ended 31 March 2025 and the Group had to pay a sum of HK\$1.8 million in full and final settlement of the claim. The over-accrued amount of approximately HK\$2.2 million was written back for the year ended 31 March 2025.

### ***Gain on disposal of a subsidiary***

During the year ended 31 March 2024, the Group disposed of the entire equity interest of its subsidiary, namely Fortune Marvel Limited, resulting in a gain on disposal of approximately HK\$0.9 million. Fortune Marvel Limited was principally engaged in property investment and held a property located in Hong Kong.

### ***Staff costs***

Staff costs amounted to approximately HK\$170.4 million and HK\$100.3 million for the years ended 31 March 2025 and 2024 respectively. The increase in staff costs was mainly due to the increase in the number of aesthetic centres of the Group as compared to the year ended 31 March 2024.

Staff costs increased further to approximately HK\$240.9 million for the year ended 31 March 2026. The increase in staff costs was mainly due to the increased number of staff as compared to the corresponding financial year in 2025.

### ***Rental and related expenses***

Rental and related expenses comprise rental payments of short-term leases, management fees, rates and government rent and license fees for the Group's medical aesthetic centres and retail/service outlets. The year-on-year growth of the rental and related expenses was approximately 57.4% and 22.9% for the year ended 31 March 2025 and 2026. The significant increase in rental and related expenses was mainly due to the new centres opened during the Track Record Period.

### *Other expenses*

The following table sets forth the breakdown of other expenses for the Track Record Period:

	<b>For the year ended 31 March</b>		
	<b>2024</b>	<b>2025</b>	<b>2026</b>
	<i>HK\$'000</i>	<i>HK\$'000</i>	<i>HK\$'000</i>
Marketing and promotion	29,597	43,068	53,472
Consultancy fee for doctors	14,873	21,288	24,443
Card commission	6,084	9,899	19,504
Staff benefit and payroll services	3,210	6,347	8,170
Repair and maintenance fees	2,818	4,238	4,829
Utilities	2,295	3,203	4,873
Office expenses	1,254	1,195	4,014
Others	2,813	4,478	8,301
	<u>62,944</u>	<u>93,716</u>	<u>127,606</u>

The year-on-year growth of the Group's marketing and promotion expense was approximately 45.5% and 24.2% for the year ended 31 March 2025 and 2026; approximately 43.1% and 14.8% for consultancy fee for doctors, which is generally in line with the increase in treatment services or procedures involving doctors; approximately 62.7% and 97.0% for card commission. Such growth is attributed to the year-on-year growth of the Group's revenue of approximately 45.4% and 35.5% for the same financial years as well as consumers' choice of payment methods with higher commission rate.

The year-on-year growth of the Group's staff benefit and payroll services for the year ended 31 March 2025 and 2026 was approximately 97.7% and 28.7%, as the Group incurred expenses relating to payroll services paid to external human resources agents of approximately HK\$1.8 million and HK\$2.4 million for each of the year ended 31 March 2025 and 2026 respectively to handle payment of salaries to cope with the significant increase in number of staff due to the Group's business expansion.

### *Net profits*

For the year ended 31 March 2024 and 2025, the Group recorded profit attributable to owners of the Company of approximately HK\$40.8 million and HK\$45.7 million respectively. The increase in profit was mainly due to the increase in revenue as compared to the year ended 31 March 2024.

For the year ended 31 March 2026, the profit attributable to owners of the Company grew to approximately HK\$54.6 million. The increase in net profit was mainly due to the continuous revenue growth during the corresponding financial year.

### *Net current assets/(liabilities)*

The net current liabilities of Group increased from approximately HK\$28.8 million as at 31 March 2024 to approximately HK\$39.8 million as at 31 March 2025, mainly due to the combined effects of: (i) the increase in trade receivables, deposits and prepayments of approximately HK\$50.4 million; (ii) the increase in bank balances and cash of approximately HK\$21.3 million; (iii) the decrease in promissory note receivables of approximately HK\$17.3 million; (iv) the increase in trade and other payables and accruals of approximately HK\$45.3 million; (v) the increase in current portion of lease liabilities of approximately HK\$20.2 million.

The Group had net current liabilities of approximately HK\$39.8 million as at 31 March 2025 and turned into net current assets of approximately HK\$12.0 million as at 31 March 2026, mainly due to: (i) the significant increase in bank balances and cash of approximately HK\$70.1 million; (ii) the increase in inventories of approximately HK\$10.1 million; and (iii) the decrease in trade and other payables and accruals of approximately HK\$32.7 million, partially offset by the increase in bank borrowings of approximately HK\$18.7.

### *Net assets*

The net assets of the Group showed an increasing trend during the Track Record Period. The Group's net assets increased from approximately HK\$60.3 million as at 31 March 2024 to approximately HK\$106.1 million as at 31 March 2025, and further increased to approximately HK\$207.1 million as at 31 March 2026. The increase in net assets were mainly attributable to the profit recorded over the years ended 31 March 2024, 2025 and 2026. The increase in net assets for the year ended 31 March 2026 was also attributed to the issuance of 18,920,000 new Shares at the subscription price of HK\$2.61 per subscription Share on 5 December 2025 with net proceeds of approximately HK\$46.7 million.

For further information about the business, financial information, management discussion and analysis, and other information of the Group, please refer to the announcements, financial reports and corporate communications published by the Company as required under the GEM Listing Rules which are available for viewing on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.fameglow.com](http://www.fameglow.com)).

See also the paragraph headed "Documents available for viewing" in this announcement for details.

## **CONTROLLING SHAREHOLDERS AND SHAREHOLDER DISTRIBUTION**

Equal Joy Holdings Limited, Mr. Yip Chun Kwok Danny, MH (an executive Director and the Chairman, "**Mr. Yip**") and Ms. Fu Chi Ching (an executive Director and the Chief Executive Officer, "**Ms. Fu**"), being controlling Shareholders of the Company, held in aggregate (i) 514,500,000 Shares, representing 64.31% of the entire issued Shares capital of the Company, as at 1 April 2023; and (ii) 466,200,000 Shares, representing approximately 56.93% of the entire issued share capital of the Company, as at the date of this announcement. Mr. Yip is the spouse of Ms. Fu. Mr. Yip, Ms. Fu and Equal Joy Holdings Limited ("**Equal Joy**") together are a group of controlling Shareholders of the Company. The Company confirms that there has been no change in controlling shareholders of the Company throughout the three years ended 31 March 2026 and up to the date of this announcement.

The Company has engaged an independent third party agent to make enquiry into its shareholding. On the basis of the Shareholders identified in the said enquiry and the disclosure of interests of the Company (the “Identified Shareholders”), to the best of the knowledge of the Directors based on information received to date and having made all reasonable inquiries, the following is the shareholding spread of the Company’s top 25 Shareholders as at 15 May 2026, being the latest practicable date for ascertaining the said shareholding spread information:

	<b>Aggregate number of Shares held by the Identified Shareholders</b> <i>(Note 1)</i>	<b>Approximate percentage of Shareholding to the issued share capital of the Company</b> <i>(Note 2)</i>
Top Identified Shareholder <i>(Note 3)</i>	466,200,000	56.93%
Top 5 Identified Shareholders	535,827,000	65.43%
Top 10 Identified Shareholders	581,821,000	71.05%
Top 20 Identified Shareholders	637,281,000	77.82%
Top 25 Identified Shareholders	657,376,000	80.27%

*Notes:*

1. Shares held by Identified Shareholders having identical names and/or same addresses or held through different brokerage firms have been aggregated and treated as being held by one single Identified Shareholder.
2. Calculated based on 818,920,000 total issued Shares.
3. Represented the aggregate shareholdings of the Controlling Shareholder Equal Joy which holds 466,200,000 Shares. All the issued shares of Equal Joy are legally and beneficially owned as to 50% by each of Mr. Yip and Ms. Fu. Accordingly, they are deemed to be interested in the 466,200,000 Shares held by Equal Joy by virtue of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Yip, Ms. Fu and Equal Joy together are a group of Controlling Shareholders of the Company.

## **SHARE OPTION SCHEME**

On 21 September 2018, the Company had approved and passed the share option scheme (the “**Share Option Scheme**”) where eligible participants may be granted options entitling them to subscribe for the Shares. The purpose of the Share Option Scheme is to advance the interests of the Company and the Shareholders by enabling the Company to grant options to attract, retain and reward the eligible persons and to provide the eligible persons an incentive or reward for their contribution to the Group and by enabling such persons’ contribution to further advance the interests of the Group.

Pursuant to the Share Option Scheme, the Company may grant options in respect of a total of 80,000,000 Shares during the term of the Share Option Scheme, representing 10% of the Company’s issued share capital as at the date of listing on GEM. As at the date of this announcement, no Shares have been granted by the Company under the Share Option Scheme and 80,000,000 Shares remain available for grant under the Share Option Scheme.


The Share Option Scheme will remain valid and effective following the Transfer of Listing to the Main Board and will be implemented in full compliance with the requirements under Chapter 17 of the Main Board Listing Rules. The listing of Shares which may be issued pursuant to the Share Option Scheme will also be transferred to the Main Board pursuant to Rule 9A.10 of the Main Board Listing Rules.

As at the date of this announcement, save for the options that were granted and may be granted under the Share Option Scheme, the Company does not have any other options, warrants or similar rights or convertible equity securities in issue which will be transferred to the Main Board.

## SHARE PRICE AND TRADING VOLUME

The following chart sets forth the share price and trading volume performance of the Shares over the Track Record Period and up to the Latest Practicable Date.

### Fameglow Holding Limited (Stock code: 8603)



Since 2025, the Company's share price has shown an overall upward trend, consistent with its strong financial performance during the Track Record Period. The positive momentum was first signaled in the interim results announcement for the six months ended 30 September 2024 published on 29 November 2024, which reflected a significant year-on-year increase in both revenue and net profit. The positive trend was confirmed by the strong full-year growth in revenue and net profit demonstrated in the annual results announcement for the year ended 31 March 2025 published on 30 June 2025.

Furthermore, the uptrend that began in February 2025 was supported by a market rebound. The average daily turnover in the Hong Kong securities market reached HKD297.3 billion in that month, representing a significant increase of 107% from January 2025 and 230% from February 2024. The market environment provided a catalyst for the initial rise in the Company's share price and helped sustain its subsequent appreciation.

On 19 November 2025, the Company announced that Evergreen Gate Limited agreed to subscribe for 18,920,000 new shares issued by the Company. The subscription has been completed on 5 December 2025.

Accordingly, the Directors are of the view that the increase in Share price and fluctuation of trading volume in or around December 2025 was mainly due to the market's positive reaction in response to the subscription of new shares by the new investor, which aligns with typical market behavior where new investor subscriptions for the company often enhance investor confidence and drives demand for the shares.

Save as disclosed above, to the best knowledge and information of the Directors after making reasonable enquiries, the Company was not aware of any reasons for such price movement since February 2025.

### **USE OF PROCEEDS FROM THE LISTING ON GEM**

On 15 October 2018, the Shares were listed on GEM by way of share offer (the “**Share Offer**”). The net proceeds received by the Company from the Share Offer, after deducting underwriting commission and professional expenses in relation to the Share Offer, amounted to approximately HK\$31.6 million. By 31 March 2021, the Group has fully utilised HK\$31.6 million of the net proceeds from the Share Offer. There has not been any material change to the use of proceeds as disclosed in the Group's prospectus dated 15 October 2018, other than the adjustment on a pro-rata basis due to the lower amount of actual net proceeds as compared to the estimated net proceeds.

### **DEALINGS IN THE SHARES OF THE MAIN BOARD**

The Shares have been accepted as eligible securities by HKSCC for deposit, clearance and settlement in the CCASS with effect from 15 October 2018. Subject to the continuing compliance with the stock admission requirements of HKSCC, the Shares will continue to be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS once dealings in the Shares on the Main Board commence, and that all activities under CCASS are subject to the General Rules of HKSCC and HKSCC Operational Procedures in effect from time to time.

Currently, the Shares are traded in a board lot size of 1,000 Shares each and are traded in Hong Kong dollars. The share registrar and transfer agent of the Company in the Cayman Islands is Conyers Trust Company (Cayman) Limited and the Hong Kong share registrar and transfer office of the Company is Tricor Investor Services Limited. The Transfer of Listing will have no effect on the existing share certificates in respect of the Shares which will continue to be good evidence of legal title and be valid for delivery, trading, settlement and registration purposes, and will not involve any transfer or exchange of the existing share certificates. Further, no change will be made to the English and Chinese stock short names, the existing share certificates, the board lot size, the trading currency of the Shares and the abovementioned share registrars and transfer offices of the Company following the Transfer of Listing.

## **GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES**

Pursuant to Rule 9A.12 of the Main Board Listing Rules, the general mandates granted by the Shareholders at the annual general meeting of the Company held on 26 September 2025 for the Directors to allot, issue and deal with new Shares and repurchase Shares will continue to be valid and remain in effect until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles or any applicable laws to be held; or (iii) the passing of an ordinary resolution by the Shareholders in general meeting revoking or varying such authority given to the Directors.

## **PUBLIC FLOAT, FREE FLOAT AND NUMBER OF SHAREHOLDERS**

### **Public Float**

Rule 8.08 of the Main Board Listing Rules requires that there must be an open market in the securities for which listing is sought. This will normally mean that for a class of securities new to listing, at least a minimum prescribed percentage of that class of securities must be held by the public at the time of listing. Where the expected market value of the class of securities at the time of listing is not exceeding HK\$6,000,000,000, the minimum prescribed percentage is 25%. Where the expected market value of the class of securities at the time of listing is over HK\$6,000,000,000 but not exceeding HK\$30,000,000,000, the minimum prescribed percentage is the higher of: (i) the percentage that would result in the expected market value of such securities held by the public to be HK\$1,500,000,000 at the time of listing; and (ii) 15%.

Based on (i) the closing price of HK\$11.28 at the Latest Practicable Date, and (ii) 818,920,000 Shares in issue, the market value of our Shares at the Latest Practicable Date is HK\$9,237.4 million. Accordingly, at least 16.2% of the total number of issued Shares must be held by the public at the time of Transfer Listing.

Apart from the 466,200,000 Shares held by Equal Joy Holdings Limited, which is legally and beneficially owned as to 50% by each of Mr. Yip Chun Kwok Danny, our Chairman of the Board and Executive Director, and Ms. Fu Chi Ching, Chief Executive Officer and Executive Director, representing in aggregate 56.93% of our total issued Shares will not count towards the public float for the purpose of Rule 8.08 of the Main Board Listing Rules. Based on information available to the Company and to the best knowledge of the Directors, Shares held by all other Shareholders will be counted towards the public float, representing 43.07% of the total issued Shares. Accordingly, the Company will satisfy the public float requirement under Rule 8.08 of the Main Board Listing Rules upon the Transfer of Listing.

### **Free Float**

Rule 8.08A of the Main Board Listing Rules provides that there must be sufficient shares for which listing is sought by a new applicant that are held by the public and available for trading upon listing. This will normally mean that the portion of the class of shares for which listing is sought that are held by the public and not subject to any disposal restrictions (whether under contract, the Main Board Listing Rules, applicable laws or otherwise), at the time of listing, must: (1) represent at least 10% of the total number of issued shares in the

class of shares for which listing is sought (excluding treasury shares), with an expected market value at the time of listing of not less than HK\$50,000,000; or (2) have an expected market value at the time of listing of not less than HK\$600,000,000.

43.07% of the total issued Shares, with a market value of approximately HK\$3,978.6 million is held by the public and not subject to any disposal restrictions (whether under contract, the Main Board Listing Rules, applicable laws or otherwise) at the Latest Practicable Date. Accordingly, the Company will satisfy the free float requirement under Rule 8.08A of the Main Board Listing Rules upon the Transfer of Listing.

## **NUMBER OF SHAREHOLDERS**

The Directors confirm that (i) not less than 25% of the total issued share capital of the Company is held by the public (as defined in the Main Board Listing Rules) as at the date of this announcement; (ii) the Company has at least 300 Shareholders; and (iii) not more than 50% of the Shares held by the public are held by the three largest public Shareholders. Accordingly, the minimum level of public float and number of Shareholders as required under Rule 8.08 of the Main Board Listing Rules have been maintained.

## **COMPLIANCE**

To the best knowledge and information of the Directors after making reasonable enquiries, there has not been any breach of GEM Listing Rules by the Company in any material respect and non-compliance of other applicable laws and regulations relating to the Group's business operations in any material respect during the Track Record Period and up to the date of this announcement, and the Group has complied with all relevant laws and regulations in Hong Kong, Macau and the PRC since the date of listing on GEM and up to the Latest Practicable Date.

As at the Latest Practicable Date, all of the Group's doctors had obtained the necessary qualifications required of them for their medical practice.

The PHFO was enacted in 2018 to regulate private healthcare facilities in Hong Kong. Under the PHFO, any private healthcare facility falling within the definition of a clinic must obtain a clinic licence. The Hong Kong government has been implementing the PHFO in phases based on the risk level of various types of private healthcare facilities. Certain of the Group's premises where doctors are practising and the relevant procedures specified under the PHFO are performed will require clinic licences under the PHFO. However, section 10(1) of the PHFO which specifies to the requirements to operate a private healthcare facility with a licence, in so far as it relates to a private healthcare facility that is a clinic, has not yet been brought into operation by gazette notice.

Pursuant to PHFO (when fully in force), a clinic must apply to and obtain a licence from the Director of Health, with the applicant being a fit and proper person and legally responsible for the facility; it must appoint a chief medical executive, a registered medical practitioner with at least 4 years' relevant experience to oversee clinical governance; the clinic must comply with the code of practice, covering standards on premises, equipment, staffing, infection control, risk management, and service delivery; it must establish proper governance, policies, and procedures, including patient safety and incident reporting systems; and it must comply with ongoing licence conditions and regulatory oversight to

maintain the licence. Our Company confirms that we have met the licensing requirements for our Group's premises that will require clinic licences. Accordingly, Our Directors confirm that there is no material financial and operational impact of the implementation of PHFO on our Group.

The Department of Health started to accept applications for clinic licences on 13 October 2025. Our Group has submitted applications for clinic licences for the centres that are applicable to the requirements under the PHFO. The relevant licence applications are still under review, and no decisions have yet been issued as at the Latest Practicable Date. The commencement of penalty provision pertaining to the operation of a clinic without a licence will be announced in due course. Before the Secretary for Health announces the commencement of the penalty clauses by notice published in the gazette, clinics can continue to operate.

As at the Latest Practicable Date, all the certificates of fire service installation and equipment of the Group remained valid. The Group has obtained all qualifications, licenses, approvals and permits that are necessary for the operation of the Group's businesses which remained valid and were in full force as at the Latest Practicable Date.

The Group received one, two and five customer complaints for each of the year ended 31 March 2024, 2025 and 2026. All the complaint cases were in relation to treatment quality and the Group made refund of approximately HK\$40,000, HK\$150,000 and HK\$62,000 for each of the year ended 31 March 2024, 2025 and 2026. Save for the above, the Group was not subject to any other material complaints, or claims by government authorities and/or customer protection organisations during the Track Record Period and up to the Latest Practicable Date.

To the best of the Directors' information and belief, save for the above, the Group is not subject to any material on-going legal disputes and/or proceedings which may have a material adverse impact on the Group's operations and financial performance during the Track Record Period and up to the date of this announcement.

## **DOCUMENTS AVAILABLE FOR VIEWING**

Electronic copies of the announcements and corporate communications published by the Company as required under the GEM Listing Rules, including the following documents, are available for viewing on the website of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the website of the Company ([www.fameglow.com](http://www.fameglow.com)):

- (a) the Company's published directors' reports and annual accounts for the year ended 31 March 2026;
- (b) the Company's published directors' reports and annual accounts for the year ended 31 March 2025;
- (c) the Company's published directors' reports and annual accounts for the year ended 31 March 2024;
- (d) the Articles;

- (e) the Company’s circular dated 31 July 2025 in respect of re-election of Directors, general mandates to repurchase and issue Shares, and notice of annual general meeting;
- (f) the Company’s circular dated 31 July 2024 in respect of re-election of Directors, general mandates to repurchase and issue Shares, and notice of annual general meeting;
- (g) the Company’s circular dated 29 August 2023 in respect of re-election of Directors, general mandates to repurchase and issue Shares, proposed amendment to the Memorandum and Articles of Association, and notice of annual general meeting; and
- (h) the Company’s circular dated 6 July 2022 in respect of re-election of Directors, general mandates to repurchase and issue Shares, and notice of annual general meeting.

## **DEFINITIONS**

In this announcement, the following expressions shall, unless the context requires otherwise, have the following meanings:

“Application”	the formal application made by the Company to the Stock Exchange for the listing of and permission to deal in the Shares on the Main Board by way of the Transfer of Listing pursuant to Chapter 9B of the Main Board Listing Rules
“Articles”	the amended and restated articles of association of the Company adopted on 29 September 2023, as amended or supplemented from time to time
“Board”	the board of Directors
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“Company”	Fameglow Holdings Limited, a company incorporated under the laws of the Cayman Islands with limited liability, the issued shares of which are listed on GEM (stock code: 8603) from 15 October 2018 to 29 June 2026 and will be listed on the Main Board (stock code: 3774) starting from 30 June 2026
“controlling shareholder(s)”	within the meaning as ascribed to it in the GEM Listing Rules
“Director(s)”	the director(s) of the Company
“GEM”	the GEM operated by the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM of the Stock Exchange, as amended, modified or supplemented from time to time
“Group”	the Company and its subsidiaries

“HK\$”	Hong Kong dollar, the lawful currency of Hong Kong
“HKSCC”	Hong Kong Securities Clearing Company Limited
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Latest Practicable Date”	17 June 2026, being the latest practicable date prior to the date of this announcement for the purpose of ascertaining certain information contained in this announcement
“Main Board”	the stock market (excluding the options market) operated by the Stock Exchange which is independent from and operated in parallel with GEM
“Main Board Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange, as amended, modified or supplemented from time to time
“Relevant Period”	A period of 250 trading days immediately preceding the Application and until the trading day immediately preceding this announcement
“Share(s)”	share(s) with a nominal value of HK\$0.01 each in the share capital of the Company
“Shareholder(s)”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Track Record Period”	The three years ended 31 March 2026
“Trading day”	for the purpose of this announcement, has the meaning as ascribed to it under note 1(c) to Rule 9B.03 of the Main Board Listing Rules
“Transfer of Listing”	the proposed transfer of listing of the Shares from GEM to the Main Board pursuant to Chapter 9B of the Main Board Listing Rules
“%”	per cent

By order of the Board  
**Fameglow Holdings Limited**  
**Yip Chun Kwok Danny, MH**  
*Chairman of the Board and Executive Director*

Hong Kong, 22 June 2026

*As at the date of this announcement, the Board comprises Mr. Yip Chun Kwok Danny, MH, Ms. Fu Chi Ching and Mr. Chung Cheuk Man as executive Directors and Mr. Kwok David, Mr. Chan Fong and Mr. Lee Pak Ming as independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules and the Main Board Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) on the "Latest Listed Company Information" page for at least seven days from the date of its publication and on the website of the Company at [www.fameglow.com](http://www.fameglow.com).*